{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:09:43Z","timestamp":1764259783620},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.leukres.2012.02.024","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T08:01:04Z","timestamp":1332403264000},"page":"e131-e132","source":"Crossref","is-referenced-by-count":8,"title":["Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib"],"prefix":"10.1016","volume":"36","author":[{"given":"Leyla","family":"Shune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzan","family":"Cayci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rogosheske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.02.024_bib0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.leukres.2012.02.024_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ajh.21409","article-title":"Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient","volume":"84","author":"Ustun","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2012.02.024_bib0015","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.02.024_bib0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.25600","article-title":"Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?","volume":"117","author":"Tefferi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.02.024_bib0025","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.leukres.2011.01.026","article-title":"Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib","volume":"35","author":"Breccia","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.02.024_bib0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1445-5994.2009.01947.x","article-title":"Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate","volume":"39","author":"Isobe","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/j.leukres.2012.02.024_bib0035","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.024_bib0040","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2012.02.024_bib0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0b013e3182263ac4","article-title":"Use of total and unbound imatinib and metabolite LC\u2013MS\/MS assay to understand individual responses in CML and GIST patients","volume":"33","author":"Streit","year":"2011","journal-title":"Ther Drug Monit"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T19:53:38Z","timestamp":1641412418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0145212612000963"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.02.024","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}